Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study

• Published in: PloS one Vol. 12; no. 11; p. e0187165
• Main Authors: Laroche, Françoise, Perrot, Serge, Medkour, Terkia, Cottu, Paul-Henri, Pierga, Jean-Yves, Lotz, Jean-Pierre, Beerblock, Karine, Tournigand, Christophe, Chauvenet, Laure, Bouhassira, Didier, Coste, Joël
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 08.11.2017; Public Library of Science (PLoS)
• Subjects: Analgesics; Analysis; Anxiety; Aromatase; Aromatase inhibitors; Aromatase Inhibitors - therapeutic use; Arthralgia; Biology and Life Sciences; Body image; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - psychology; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Cohort analysis; Cohort Studies; Complications and side effects; Confidence Intervals; Consent; Development and progression; Estrogens; Female; Follow-Up Studies; Health risk assessment; Hospitals; Humans; Inhibitors; Internal medicine; Medicine and Health Sciences; Middle Aged; Muscle pain; Neuralgia; Neuropathy; Nonsteroidal anti-inflammatory drugs; Oncology; Pain; Pain management; Personality; Quality of life; Quality of Life - psychology; Regression Analysis; Regression models; Side effects; Social Sciences; Studies; Taxane; Taxanes; Womens health; France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0187165

Women with hormone-dependent breast cancer are treated with aromatase inhibitors (AI) to slow disease progression by decreasing estrogen levels. However, AI have adverse effects, including pain, with potentially serious impact on quality of life (QOL) and treatment compliance. We evaluated quality of life during the first year of AI treatment, focusing particularly on the impact of pain. In a multicenter cohort study of 135 women with early-stage breast cancer, free of pain at the initiation of AI treatment, quality of life (by the EORTC QLQ-BR23), somatic and psychic symptoms, psychological characters, temperament and coping strategies were assessed at baseline and at each follow-up visit (1, 3, 6 and 12 months). The impact of treatment-induced pain on quality of life during follow-up was determined with repeated-measures regression models. These models were constructed to assess the effects of pain and pain type on quality of life during follow-up, taking into account predictors associated with quality of life at baseline. Prior ganglion resection, taxane treatment and chemotherapy, a high amplification score on the pain catastrophizing scale, and a high harm avoidance score on the personality questionnaire were associated with a significantly lower baseline QOL. Fifty-seven percent of women developed pain of five different types: upper or lower limb joint pain, diffuse pain, neuropathic pain, tendon pain and mixed pain. A significant decrease in QOL was noted in the women with pain, particularly for body image, sexual functioning and future perspectives. Moreover, the impact of pain on QOL depended on the type of pain experienced. In conclusion, women treated with aromatase inhibitors display changes in quality of life and the degree of change in quality of life depends mostly on the type of pain experienced. Oncologists and patients should be aware of painful adverse effects of AI and encouraged to provide or receive earlier and more appropriate management of these effects.